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Abstract
Background: Hyperplastic Polyposis Syndrome (HPS) is a condition associated with multiple serrated polyps, and an
increased risk of colorectal cancer (CRC). At least half of CRCs arising in HPS show a CpG island methylator phenotype
(CIMP), potentially linked to aberrant DNA methyltransferase (DNMT) activity. CIMP is associated with methylation of tumor
suppressor genes including regulators of DNA mismatch repair (such as MLH1, MGMT), and negative regulators of Wnt
signaling (such as WIF1). In this study, we investigated the potential for interaction of genetic and epigenetic variation in
DNMT genes, in the aetiology of HPS.
Methods: We utilized high resolution melting (HRM) analysis to screen 45 cases with HPS for novel sequence variants in
DNMT1, DNMT3A, DNMT3B, and DNMT3L. 21 polyps from 13 patients were screened for BRAF and KRAS mutations, with
assessment of promoter methylation in the DNMT1, DNMT3A, DNMT3B, DNMT3L MLH1, MGMT, and WIF1 gene promoters.
Results: No pathologic germline mutations were observed in any DNA-methyltransferase gene. However, the T allele of
rs62106244 (intron 10 of DNMT1 gene) was over-represented in cases with HPS (p,0.01) compared with population
controls. The DNMT1, DNMT3A and DNMT3B promoters were unmethylated in all instances. Interestingly, the DNMT3L
promoter showed low levels of methylation in polyps and normal colonic mucosa relative to matched disease free cells with
methylation level negatively correlated to expression level in normal colonic tissue. DNMT3L promoter hypomethylation
was more often found in polyps harbouring KRAS mutations (p=0.0053). BRAF mutations were common (11 out of 21
polyps), whilst KRAS mutations were identified in 4 of 21 polyps.
Conclusions: Genetic or epigenetic alterations in DNMT genes do not appear to be associated with HPS, but further
investigation of genetic variation at rs62106244 is justified given the high frequency of the minor allele in this case series.
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Introduction
Hyperplastic Polyposis Syndrome (HPS) is a colorectal cancer
(CRC) predisposition associated with the development of multiple
serrated polyps, and is defined by the World Health Organization
as:
(1) at least five serrated polyps proximal to the sigmoid colon
with two or more of these being .10 mm; or
(2) any number of serrated polyps proximal to the sigmoid colon
in an individual who has a first-degree relative with serrated
polyposis; or
(3) .20 serrated polyps of any size, but distributed throughout
the colon. The implied meaning of this last criterion is that the
polyps are not all present in the rectum [1].
HPS is the genetic disease model for the serrated neoplasia pathway
of CRC development [2–4]. This new distinct pathway of CRC is
characterized by activating mutation of the BRAF proto-oncogene
(specifically V600E) and widespread and concordant gene
promoter hypermethylation (CpG Island methylation Phenotype
or CIMP) [5–8], and is responsible for silencing of many genes by
CpG island methylation in specific cancer subtypes [9]. CIMP
positive CRC cancers have distinct clinico-pathological features
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preponderance, and a high frequency of BRAF mutation [7,10–
12]. DNA methylation disturbances are also a feature of HPS with
a large proportion of BRAF mutation positive HPS polyps being
CIMP positive [13,14]. Increased DNA methylation in 14 markers
(MINTs 1,2 and 31, p16, MGMT, MLH1, RASSF1, RASSF2,
NORE1, RKIP, MST1, DAPK, FAS and CHFR) in small hyperplastic
polyps and in normal mucosa of patients with HPS suggests that
there may be a genetic basis for this observation [6].
The aberrant DNA methylation found in the CIMP phenotype
may be a consequenceof a dysfunction inthe machineryinvolved in
establishing and maintaining normal DNA methylation [15]. DNA
methyltransferases (DNMTs) are a family of proteins responsible for
transfer of methyl groups specifically to cytosine in CpG
dinucleotides of DNA [16,17]. Four DNMTs (DNMT1 [18],
DNMT3A, DNMT3B [19–21], and DNMT3L [22,23]) have been
extensively characterized in mammals. DNMT1 acts primarily on
hemi-methylated double stranded DNA following DNA replication
to faithfully maintain methylation patterns in daughter cells [24,25].
DNMT3A and -3B are involved in de novo methylation, establishing
tissue-specific DNA methylation marks during development
[26,27]. DNMT3L lacks the methyltransferase catalytic domain
[28] and is thought to facilitate the action of other DNMTs by
enhancing their targeting to specific loci for DNA methylation [29].
Dysregulation of DNMTs has been linked to many cancers [30],
and may play a role in the CIMP phenotype in CRC [31]. Indeed
recent evidence suggests that overexpression of DNMT3B in
particular shows a significant association with CIMP high CRC
[32,33]. Given the observation that even apparently normal
mucosa in patients with HPS is highly methylated [6], we
investigated the potential for mutation or epigenetic disruption of
DNMT1 (CCDS12228.1), DNMT3A (CCDS1718.1), DNMT3B
(CCDS13204.1) and DNMT3L (CCDS13705.1) in the develop-
ment of HPS.
Materials and Methods
Patient Selection
The Melbourne Health Human Research Ethics Committee
approved the study (HREC2007.081) and all participants
provided written informed consent to take part. We utilized the
clinical database of The Royal Melbourne Hospital Bowel Cancer
Surveillance Service and the Familial Cancer Clinic, to identify
patients satisfying the diagnostic criteria for HPS. Detailed patient
demographics, polyp number, size, location, pedigree, family and
personal history of CRC and histopathology were prospectively
collected (Table 1 and Table 2).
DNA sequence data on this paper have been previously
reported on the GenBank database.
Polyps were reviewed by a histopathologist with an interest in
the HPS (CD). The use of the term serrated polyp in this report
encompasses polyps with serrated architecture and includes micro-
vesicular hyperplastic polyps, and sessile serrated polyps with or
without dysplasia. Traditional serrated adenoma and adenoma
were not considered in this report. We classified lesions as
advanced polyps if the size of the lesion was 10 mm or more.
Control colon tissue was obtained during colonoscopy from
patients who presented with abdominal pain for investigation and
completed endoscopic examination was normal.
Peripheral blood was collected for germline mutation analysis
and immortalized EBV transformed lymphoblast cell lines (LCLs)
were generated. If surveillance colonoscopy was performed, polyp
tissue was collected and stored in RNALater (Ambion-Applied
Biosystems).
Total DNA extraction
LCLs (lymphoblast cell lines) were available from 45 patients
with HPS. DNA was extracted from all cases using DNeasy 96
Blood and Tissue kits according to the manufacturer’s instructions
(Qiagen, Hilden, Germany). In addition, DNA was extracted from
Table 1. Patients’ demographics.
Number of cases with HPS 45
Median age years (range) 61 (28–82)
Female 21
Median age at diagnosis 49 (26–78)
Median number of HP per case 37.5
Number of patients with HPs .10 mm 18
Patients with 5 or more coexisting adenomas 13
Number of cases who had partial/total colectomy for
CRC/HPS
11/5
Number of families with HPS 2
Number of patients with FHx of CRC (FDR) 20
Personal history of CRC 11
Median age of patients with CRC 47.5
Thirty-six cases from this cohort have been previously reported [66]. CRC-
colorectal cancer, FDR-first degree relative.
doi:10.1371/journal.pone.0016831.t001
Table 2. Clinico-pathological characteristics of cases: DNMT
promoter methylation analysis and BRAF/KRAS mutation.
Cases HPs location
Classification
of polyps Size
BRAF/KRAS
mutation
1 Sigmoid colon SSA 10 mm KRAS
2 Descending colon SSA 8 mm WT
3 Rectum MVHP 5 mm KRAS
Transverse colon MVHP 6 mm KRAS
Transverse colon MVHP 7 mm WT
4 Sigmoid colon MVHP-SSA 9 mm BRAF
Sigmoid colon MVHP 5 mm BRAF
5 Transverse colon MVHP 6 mm BRAF
Splenic flexure MVHP 5 mm BRAF
6 Descending colon HP 9 mm BRAF
7 Ascending colon SSA 7 mm BRAF
Transverse colon Mixed HP/SSA 5 mm KRAS
Descending colon SSA 9 mm BRAF
8 Rectum SSA 5 mm BRAF
9 Ascending colon SSA 12 mm WT
10 Rectum SSA 4 mm BRAF
11 Transverse colon Mixed
HP/SSA
6m m W T
12 Transverse colon SSA 8 mm BRAF
Transverse colon SSA 5 mm WT
13 Rectum SSA 9 mm BRAF
Sigmoid colon HP 5 mm WT
SSA-sessile serrated polyp; HP-typical hyperplastic polyp; MVHP- microvesicular
hyperplastic polyp.
doi:10.1371/journal.pone.0016831.t002
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concentration and quality was assessed by absorbance spectro-
photometry and agarose gel electrophoresis.
RNA Isolation and Real-Time Reverse-Transcription PCR
Total RNA was isolated using Trizol Reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions,
followed by treatment with Turbo DNA-free (Ambion/Applied
Biosystems, Austin, TX, USA) to remove contaminating genomic
DNA. Reverse transcription using random hexamers was
performed with SuperScript VILO cDNA Synthesis Kit (Invitro-
gen). To determine expression levels of genes of interest,
quantitative RT-PCR using SYBR Green-based analysis and
Master Mix (Invitrogen) was carried out with 10 mM sense and
antisense primers (primers on request). Reactions were performed
in triplicate and analysed using an ABI 7300 Sequence Detection
System (Applied Biosystems). Relative expression levels were
determined using the standard DCt method with GAPDH
housekeeping gene used for normalisation.
Germline mutation detection
We employed High Resolution Melting (HRM) analysis as a novel
and cost effective method to search for the presence of unknown
variants in DNMT genes, from 45 cases with available genomic DNA.
DNA was first amplified by real time PCR in the presence of
LightCyclerH 480 High Resolution Melting Dye using a LightCyclerH
480 System (Roche Applied Sciences). After the PCR, the successive
melting curve experiment was performed in the same apparatus. Gene
scanning software was used to identify sequence variation by melt
profiling. PCR and DNA melting were performed in triplicate. PCR
was optimized with titration of MgCl2 and variation in annealing
temperatures. In brief, 10 ng genomic DNA was used in the PCR,
Master mix (Roche Applied Sciences), and final forward and reverse
primer (concentration 0.2 mM). Sense and antisense PCR primers for
DNMT genes were designed using consensus coding sequences:
DNMT1 (CCDS12228.1), DNMT3A (CCDS1718.1), DNMT3B
(CCDS13204.1) and DNMT3L (CCDS13705) [34]. When amplicon
length exceeded 300 bp or nonspecific product was evident following
electrophoresis on a 2% agarose gel, we designed alternative primer
pairs using the Primer3 software package (http://biotools.umassmed.
edu/bioapps/primer3_www.cgi). The online POLAND program was
used to confirm that amplicons contained a single melting domain [35].
Somatic mutation detection for BRAF and KRAS
High resolution melting (HRM) analysis was performed using a
LightCyclerH 480 (Roche Diagnostics, Penzberg, Germany) in a
modification of the previously published method of [36]. The
reaction mixture contained: 1x PCR buffer, DNA template,
200 uM dNTPs (Fisher Biotec Australia, Wembley, Western
Australia), 5 mM SYTOH 9 (Invitrogen, Carlsbad, CA), and 0.5 U
HotStarTaq polymerase (Qiagen, Germantown, MD, USA).
Various concentrations of MgCl2 and primers (primers on request)
were used specific to each assay in a 10 ml final reaction volume.
PCR reactions were performed in triplicate.
Quantitative DNA methylation analysis by MALDI-TOF
MassARRAY EPITYPING and bisulphite sequencing
DNA was extracted from 21 polyps (13 cases with HPS) and 5
controls (colonic mucosa from non-HPS cases) using the DNeasy
kit (Qiagen). Bisulphite conversion was performed using the
MethylEasy Xceed kit according to manufacturer’s instructions
(Human Genetic Signatures, Sydney, Australia) 1–2 mgo f
genomic DNA was used for bisulphite conversion. The converted
DNA was eluted to a final concentration of 20 ng/ml. 20 ng of
converted DNA was used for PCR amplification.
We employed SEQUENOM EpiTYPER analysis [37] for
detection and quantitation of DNA methylation of the promoter
regions of DNMT1, DNMT3A, DNMT3B and DNMT3L. In brief,
genomic DNA was bisulphite treated using MethylEasy Xceed kit
(Human Genetic Signatures), PCR amplification was performed
using primers directed to the promoter regions of the DNMT genes
(primers on request). Amplicons were then subjected to the
EpiTYPER chemistry. Briefly, amplicons were treated with
shrimp alkaline phosphatase treatment followed by in vitro
transcription and base specific cleavage (SEQUENOM, San
Diego, CA). Samples were then analysed by MALDI-TOF mass
spectroscopy and the methylation ratios obtained using EpiTY-
PER v1.0.5 software (SEQUENOM). Further analysis and
cleaning of data was performed using the R statistical package
(http://www.cran.org) and scripts developed in house. This
included identification and removal of CpG units that overlapped
with other peaks following mass spectroscopy. Further data
cleaning and curation was then performed in R to remove CpG
units that did not yield data in at least 70% of samples. Samples,
from which less than 40% of CpG units yielded data, were also not
included in subsequent analyses.
The DNMT3L amplicons were subjected to cloning and DNA
sequencing as outlined in [38]. Amplicons were cloned into
pGEMT-Easy Vector (Promega, Madison, WI, USA) and then
transformed into DH5-a E. coli. Positive clones were selected for
automated DNA sequencing performed by the Australian Genome
Research Facility (AGRF, Melbourne, Australia). Sequencing data
was then analysed using BiQ-Analyzer [39].
Statistical analysis
After data cleaning and curation of SEQUENOM assays, data
was analysed using the Heatmap.2 function in R whereby
unsupervised hierarchal clustering of the samples and CpG units
was performed. Dendrograms and associated heatmaps were
generated according to the DNA methylation ratio of specific CpG
units and samples analysed. Geometric means methylation levels
were calculated for each tissue type, prior to statistical analysis
using a Student’s t-test.
A box and whisker plot was generated in R to display the
distribution of DNA methylation ratios between polyp and
germline tissues across the DNMT3L promoter. Calculations were
performed to estimate odds ratios (ORs) and 95% confidence
intervals (95% CIs) for the associations between allele frequency
and disease. All statistical tests were two-sided and P-value, 0.05
was considered as a significant level of statistical evidence to reject
the null hypothesis. All statistical analyses were done using Stata
10.0.
Results
DNA methyltransferase exon scanning by High
Resolution Melting (HRM) Analysis
In order to ascertain whether the previously reported methyl-
ation disruption associated with HPS may be due to genetic
variability in DNMTs, we screened a total of 92 DNMT exons for
novel mutations by HRM analysis in LCL genomic DNA from
HPS subjects. This comprised 40 exons from DNMT1, 17 from
DNMT3A, 24 from DNMT3B and 11 from DNMT3L. We found
three previously identified single nucleotide polymorphisms (SNPs)
in DNMT1 (synonymous rs721186 and rs2228613) and intronic
(rs62106244) and one SNP in DNMT3A (synonymous rs2276598)
(Table 3).
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present in 7 out of 45 cases all of whom were heterozygous. To
establish the frequency of this uncharacterised variant in the
Caucasian population generally, we scanned 300 control samples,
and found 16 that were heterozygous at this site. Chi-square
analysis confirmed a statistically significant over representation of
both the CT genotype and T allele in HPS cases (x
2=6.66,
p=0.01; x
2=7.45, p,0.01 respectively). We observed that cases
with HPS were approximately three times more likely to carry the
variant (15.6%) compared to controls (5.3%), and this difference
was statistically significant (p=0.01). However, given the rarity of
the variant the confidence intervals were wide (relative risk =2.9;
95% confidence interval 1.1 to 6.5). DNMT3B and DNMT3L exon
scanning did not reveal any SNPs in our HPS cases.
Quantitative methylation analysis of CRC CIMP-
associated genes and DNMTs
Previous studies using a small number of patients with HPS and
methylation specific PCR (MSP) have identified elevated levels of
specific promoter methylation in both polyps and normal mucosa
relative to non-diseased mucosa from subjects with sporadic
serrated polyps [6]. This includes methylation of the MGMT and
MLH1 genes. In this study, we measured DNA methylation of the
IGF2 differentially methylated region (DMR), H19, MGMT,
MLH1 and WIF1 promoters. Contrary to previous reports [40];
[13,14] we found that, MGMT and MLH1 were unmethylated
(Fig. S1) in both polyps and matched normal mucosa, while there
was no significant difference in DNA methylation of IGF2, H19,
and WIF1 (Fig. S1) between polyp and disease free tissue.
In addition to examining CIMP markers, we also examined the
potential for methylation based dysregulation of the DNMT genes
themselves. Little data is available regarding methylation status of
this family of genes in non-diseased somatic tissue, and only
limited studies have examined this in disease [41,42]. We studied
DNA methylation of the promoter region of the DNMT1, -3A and
-3B genes in HPS cases, comparing polyp-derived DNA, normal
mucosa from the same patient (where available), and mucosa from
controls with no disease. All three promoter regions were generally
unmethylated in both polyp and normal mucosal tissue, with less
than 10% methylation detected by SEQUENOM EpiTYPER
(data not shown). We also found no evidence of promoter
methylation of these genes in LCL genomic DNA (data not
shown).
Interestingly, we found that DNMT3L was hypomethylated in both
normal gut mucosa (mean methylation 0.33, SD 0.24, n=12) and
polyp tissue (mean methylation 0.36, SD 0.25 n=21) relative to
matched LCL DNA (mean 0.57, SD 0.24 n=19); see unsuper-
vised clustering figure 2A and box and whisker plot figure 2B).
This difference was highly significant (p=5.1610
29 Student’s t-
test) and was confirmed by bisulphite sequencing (Fig. 3). We were
unable to test expression level directly in HPS samples due to a
lack of RNA, however a negative correlation between mean
methylation and expression level was found in normal colonic
tissue (R= 20.64; Fig. 4).
KRAS mutation may correlate with DNMT3L promoter
methylation
CIMP and BRAF mutation are hallmarks of serrated tumours
and BRAF V600E has been proposed as an important biological
marker for HPS specific cancers [43]. We performed BRAF
(V600E) and KRAS screening with HRM on DNA from serrated
polyps derived from HPS cases and controls. Consistent with
previous published data [7,44] we found that the BRAF V600E
mutation was common in serrated polyps (11 out of 21) whereas
the KRAS mutation was evident in only 4 out of 21. KRAS
mutations were found primarily in polyps located in the transverse
colon (two) and rectum (two). Interestingly one patient had two
polyps with the BRAF somatic mutation and one with the KRAS
somatic mutation, all within the right colon from the same patient.
Examination of the level of DNMT3L promoter methylation and
KRAS mutation-containing polyps revealed an association between
these distinct genetic and epigenetic modifications (Table 4).
Polyps with KRAS mutations were far more likely to show
DNMT3L promoter methylation at levels similar to those found in
LCLs (p=0.0053). In contrast, polyps with the BRAF mutation did
not show any significant association with DNMT3L promoter
methylation.
Table 3. SNPs identified with HRM on germline DNA.
Gene SNP ID Exon/Intron DNA change
Clinical
association
DNMT1 rs721186 Exon C/T Unknown
DNMT1 rs62106244 Intron C/T Unknown
DNMT1 rs2228613 Exon A/C Unknown
DNMT3A rs2276598 Exon C/T Unknown
doi:10.1371/journal.pone.0016831.t003
Figure 1. Normalized and temp-shifted difference plot for DNMT1 gene SNP rs62106244. *Seven cases were heterozygous for rs62106244.
The top arrow shows the sequence of the DNMT1 gene.
doi:10.1371/journal.pone.0016831.g001
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Given the significant association of HPS and associated tumours
with increasing levels of aberrant promoter methylation (CIMP),
including extensive methylation in the normal mucosa, and the
role of DNMTs in both the establishment and maintenance of
DNA methylation in humans, we examined the potential
association of genetic and epigenetic disruption of DNMTs in
HPS.
Genetic variation is the DNMT1 gene is potentially
associated with HPS
Variants in DNMT1 have been identified as risk factors for
disease including systemic lupus erythematosus [45]. Genetic
deficiency of DNMT3B causes ICF syndrome, a recessive human
disorder characterised by immunodeficiency, centromere instabil-
ity, and facial anomalies [46]. Variants in other DNMTs (i.e.
DNMT3L, DNMT1) have been associated with human cancers
[47–50]. Recently, a rare variant of DNMT3L was specifically
associated with reduced methylation of sub-telomeric regions in
humans [51]. In this study we demonstrated that HPS is not
Figure 2. Unsupervised hierarchical clustering of the level of methylation of DNA from LCLs and somatic DNA in HPS cases for
CpG_1 (analytic unit 1), CpG_6.7 (unit 2), CpG_8 (unit 3) and CpG_10 (unit 6) of the DNMT3L promoter region (A); Box and whisker
plot comparing quantitative methylation between polyp tissue (white boxes) and peripheral blood (grey boxes) for each CpG site
(B).
doi:10.1371/journal.pone.0016831.g002
Figure 3. DNMT3L bisulphite sequencing: HP40RH_LCL lym-
phoblastic cell line DNA, HP40RH_P polyp DNA and normal
mucosa DNA HP40RH_N. Each line represents a sequenced clone
and DNA methylation information is presented as a circle denoting the
CpG site where methylation could occur. Black circles represent
methylated CpG’s while white circles represent unmethylated CpG’s.
The promoter of DNMT3L was observed to be less methylated in normal
mucosa and polyp tissue but methylated in lymphoblastic cell line DNA.
doi:10.1371/journal.pone.0016831.g003
Figure 4. Correlation between mean methylation of DNMT3L
promoter and gene expression level in control mucosa tissue.
Mean was calculated from the combined methylation values for CpG
units, 1, 2, 3 and 6.
doi:10.1371/journal.pone.0016831.g004
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genes. Although we identified SNPs in both DNMT1 and
DNMT3A in HPS cases, these were generally detected at similar
frequencies in non-diseased subjects and were predicted to be non-
pathogenic.
The exception was rs62106244, located in the DNMT1 gene, that
was found to have a significantly higher frequency in HPS cases in
comparison with controls. This SNP is not predicted to alter
DNMT1 splicing or protein, and is not evolutionarily conserved
beyond primates [52]. Corresponding intronic SNPs, in other
genes, have previously been associated with many diseases,
including some cancers [53]. In fact as many as 45% of all trait/
disease-associated SNPs identified in genome-wide association
studies are intronic [54] with the pathogenic mechanisms
underlying such associations remaining largely unclear. In addition,
the level of linkage disequilibrium (LD) of rs62106244 in relation to
other variants (i.e. haplotype status) has not yet been determined,
although the entire DNMT1 gene lies in a large block of LD.
Common CIMP markers are absent in most HPS lesions
Perturbation of DNA methylation and loss of gene function is
well documented in MSI-H CRC [55]. However, the role of
aberrant DNA methylation in precancerous lesions remains poorly
understood despite its widespread occurrence. It has been reported
that alteration of DNA methylation in hepatocellular carcinoma
(HCC) evolves through precancerous lesions to multistage
hepatocarcinogenesis [56]. In comparison with non-diseased
tissue, human cancers generally show variations in both global
DNA methylation (hypomethylation) and gene-specific (hyper- or
hypo methylation) status [16,57].
Promoter methylation of MLH1 in MSI-H sporadic colon
cancers represents a classical example of aberrant methylation
leading to cancer [12]. We did not find any evidence of aberrant
methylation in HPS ‘‘precancerous lesions’’ for this traditional
CIMP marker or for the MGMT gene. DNA methylation at other
markers (IGF2 WIF1 and H19) was also found to be unaffected in
this group of HPS cases. MLH1 methylation is associated with
high-level MSI and this is in turn usually observed in areas of
dysplasia or overt carcinoma. Similarly, methylation of MGMT is
more likely to be seen in conjunction with KRAS mutation. Our
findings in polyps therefore are not inconsistent with published
reports.
DNMT3L is specifically hypomethylated in gut mucosa
and HPS
Our data from a candidate gene approach to explore epigenetic
abnormalities in HPS revealed a general lack of DNMT1,
DNMT3A and DNMT3B methylation as expected in non-diseased
mucosal tissue. However, DNMT3L, usually silenced in somatic
tissues by methylation, was found to be hypomethylated in both HPS
polyps and normal gut mucosa relative to LCLs. There was no
statistically significant difference between matched normal mucosa
and polyps derived from the same cases, or between colonic
mucosa from HPS cases and controls (colonic mucosa from cases
with normal endoscopic findings and no history of polyps). We also
found elevated methylation levels in all other somatic tissues tested
including kidney, peripheral blood mononuclear cells, skeletal
muscle, brain, and skin fibroblasts (data not shown), suggesting
that the decreased methylation seen in gut mucosa is of functional
significance. This was further supported by gene expression
analysis that confirmed a inverse correlation between mean
methylation and gene expression levels. In mice, methylation of
the DNMT3L promoter has been unequivocally linked to gene
silencing [58], and it has been shown that this gene is primarily
expressed in thymus, testis and ovaries [23,59]. We have now
added gut mucosa to the list of tissues expressing this gene.
Recently the loss of DNA methylation at the DNMT3L promoter
was found to be a positive biomarker for cervical cancer [60].
DNMT3L over expression in cervical cancer cells increases
cellular proliferation, anchorage independent growth and nuclear
reprogramming of cells, all central events in tumour development
[61].
An interaction between DNMT3L methylation and KRAS
mutation?
Previous studies that have examined the relationship between
BRAF and KRAS mutations in a wide range of colonic polyp and
cancer tissue have found a mutually exclusive distribution of these
mutations [7]. DNMT3L methylation percentage across all CpG
sites analysed for cases with BRAF and KRAS mutation revealed
increased methylation of the DNMT3L promoter in cases with a
KRAS mutation when compared with polyps with the normal
variant (p=0.0053), however due to small number of cases this
observation need to be investigated in a larger number of polyps
harbouring KRAS mutation. Additionally we found both BRAF and
KRAS mutations in a single case (two polyps harbouring BRAF
mutation and one polyp with KRAS mutation), which, though
relatively rare, has been previously described [44]. Lesions
harbouring KRAS mutations have been associated with distal
location within the colorectum [62] MSI-L status [63] and
unfavourable prognosis [64]. Our findings with regard to
DNMT3L methylation and KRAS mutation need to be investigated
further as recently aberrant promoter hypomethylation of
DNMT3L has been linked with cervical cancer tumorigenesis
[60]. The increased DNMT3L methylation seen in KRAS mutated
Table 4. Quantitative methylation (%) of DNMT gene promoters: 21 serrated polyps stratified by BRAF and KRAS mutation.
Mean DNMT1
methylation (%)
Mean DNMT3A
methylation (%)
Mean DNMT3B
methylation (%)
Mean DNMT3L
methylation (%)
Polyps with BRAF mutation 3.3‘ 4.3‘ 21‘ 37*
Polyps with
KRAS mutation
2.8‘ 4.1‘ 27‘ 55**
Polyps WT for BRAF and KRAS 3.6 4.4 25 30
‘p-value ,0.05 for DNMT1, DNMT3A and DNMT3B.
*p-value =0.147 (BRAF/WT).
**p-value: =0.0053 (KRAS/WT).
doi:10.1371/journal.pone.0016831.t004
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generally seen in these polyps relative to those with BRAF
mutations.
Conclusions
To date, there is no single genetic abnormality known to
underlie HPS. In addition, factors determining the transition to
colon carcinoma remain unknown. There have been several
reports implicating DNMT dysregulation in carcinogenesis
[41,65]. However, the degree to which DNMTs may contribute
to the development of precancerous lesions remains poorly
understood. This study represents the first investigation of the
possible role of the DNMT family of genes in the development of
HPS. The data generated do not exclude a functional role of
DNMT dysregulation in the development of HPS and associated
disorders, however no exonic germline mutations were discovered,
suggesting that regulation of DNMTs may occur via alternative
mechanisms in this condition. It is interesting to speculate that the
observed hypomethylation of the DNMT3L promoter in normal
gut mucosa in the HPS patients identified here, may also play a
role in the aberrant de novo establishment of tumour suppressor
methylation seen in most CRC.
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